TSHA

Peers: NGNE ACAD QURE SRPT RGNX STOK SLDB VYGR ABEO RCKT

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA FESM VHT

Index	RUT
Market Cap	1.38B
Enterprise Value	984.63M
Income	-149.63M
Sales	5.49M
Book/sh	1.19
Cash/sh	1.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	99
IPO	Sep 24, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	251.94
P/B	3.57
P/C	3.04
P/FCF	-
EV/EBITDA	-
EV/Sales	179.35
Quick Ratio	17.76
Current Ratio	17.76
Debt/Eq	0.15
LT Debt/Eq	0.14
Option/Short	Yes / Yes

EPS (ttm)	-0.43
EPS next Y	-0.52
EPS next Q	-0.13
EPS this Y	-46.61%
EPS next Y	-5.03%
EPS next 5Y	10.86%
EPS past 3/5Y	55.14% 36.86%
Sales past 3/5Y	57.49% -
EPS Y/Y TTM	-21.09%
Sales Y/Y TTM	-32.27%
EPS Q/Q	-40.13%
Sales Q/Q	-100.00%
Earnings	Nov 12 BMO
EPS/Sales Surpr.	-14.74% -100.00%

Insider Own	15.79%
Insider Trans	-0.39%
Inst Own	86.95%
Inst Trans	9.93%
ROA	-37.23%
ROE	-47.05%
ROIC	-33.79%
Gross Margin	78.65%
Oper. Margin	-2854.91%
Profit Margin	-2728.04%
SMA20	4.40%
SMA50	-7.27%
SMA200	-19.99%
Trades

Shs Outstand	325.30M
Shs Float	274.37M
Short Float	18.68%
Short Ratio	14.13
Short Interest	51.25M
52W High	7.30 -41.85%
52W Low	3.45 22.87%
Volatility	7.94% 7.47%
ATR (14)	0.28
RSI (14)	48.84
Beta	1.31
Rel Volume	0.35
Avg Volume	3.63M
Volume	753,442

Perf Week	3.79%
Perf Month	2.54%
Perf Quarter	-33.72%
Perf Half Y	-38.03%
Perf YTD	-22.82%
Perf Year	9.13%
Perf 3Y	182.06%
Perf 5Y	-73.03%
Perf 10Y	-
Recom	1.08
Target Price	13.00
Prev Close	4.37
Price	4.24
Change %	-2.86%

Consensus

Strong Buy

Avg. Price Target

$13.00

Implied Upside

+206.2%

Analysts19incl. previous ratings

Rating Distribution16 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 17, 2026	Initiated	WWolfe Research	Outperform
Oct 21, 2025	Initiated	RRaymond James	Strong Buy	$13	+206.2%
Jul 11, 2025	Initiated	BBofA Securities	Buy	$8	+88.5%
Jun 27, 2024	Initiated	BBMO Capital Markets	Outperform	$5	+17.8%
Apr 09, 2024	Initiated	PPiper Sandler	Overweight	$9	+112.0%
Feb 01, 2023	Downgrade	JJefferies	Buy → Hold	$14 → $1.50	-64.7%
Jan 27, 2023	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$23 → $3	-29.3%
Nov 09, 2022	Downgrade	GGoldman	Buy → Neutral	$16 → $3	-29.3%
Mar 09, 2022	Initiated	RRobert W. Baird	Outperform	$26	+512.5%
Mar 01, 2022	Initiated	WWells Fargo	Overweight	$25	+488.9%
Feb 18, 2022	Initiated	SSMBC Nikko	Outperform	$25	+488.9%
Dec 16, 2021	Initiated	GGuggenheim	Buy	$28	+559.6%
Jul 16, 2021	Initiated	NNeedham	Buy	$45	+960.1%
Jun 24, 2021	Initiated	TTruist	Buy	$60	+1,313.4%
Jun 15, 2021	Initiated	BBTIG Research	Buy	$44	+936.5%
Jun 09, 2021	Initiated	WWedbush	Outperform	$31	+630.3%
Jun 08, 2021	Initiated	JJMP Securities	Mkt Outperform	$40	+842.3%
May 19, 2021	Initiated	CCantor Fitzgerald	Overweight	$44	+936.5%
May 11, 2021	Resumed	JJefferies	Buy	$34 → $45	+960.1%
Feb 24, 2021	Initiated	WWilliam Blair	Outperform

Nov-06-26 05:38PM	Taysha Heads Into Q3 With Pivotal Dosing Done, A Fat Cash Cushion And A Stock Down A Third (Earnings Whispers) +5.87%
08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-05-26 08:00AM	Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12 (GlobeNewswire) -6.19%
Oct-02-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-26 08:00AM	Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Sep-04-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-26 01:02AM	Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ... (GuruFocus.com)
Aug-11-26 04:00PM	Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-04-26 04:00PM	Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 (GlobeNewswire) +7.27%
Aug-03-26 08:00AM	Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome (GlobeNewswire)
Jun-25-26 04:01PM	Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting (GlobeNewswire) -10.52%
Jun-24-26 10:33PM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jun-22-26 08:56AM	Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA) (InvestorsHub)
08:00AM	Loading…
08:00AM	Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome (GlobeNewswire)
Jun-05-26 08:01AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.62%
May-06-26 08:00AM	Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-26 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-29-26 08:00AM	Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6 (GlobeNewswire)
Apr-27-26 05:21PM	Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting (GlobeNewswire)
Apr-03-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-19-26 03:03PM	Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
08:00AM	Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-26 09:17AM	Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-12-26 08:00AM	Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19 (GlobeNewswire)
Mar-06-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-26 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-02-26 09:37AM	Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress (Insider Monkey)
Jan-29-26 01:48PM	Here's What Analysts Are Saying About Taysha Gene Therapies (TSHA) (Insider Monkey)
02:13PM	Loading…
Jan-14-26 02:13PM	Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects (Insider Monkey)
Jan-06-26 08:00AM	Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome (GlobeNewswire) +7.57%
Dec-21-25 07:31AM	Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program (Insider Monkey)
Dec-05-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.92%
Nov-18-25 06:17AM	Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? (Insider Monkey)
Nov-07-25 09:34PM	Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) (Insider Monkey)
Nov-04-25 04:09PM	Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -5.62%
07:00AM	Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-25 07:41AM	What To Expect From Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings (GuruFocus.com) -10.08%
Oct-28-25 08:00AM	Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 (GlobeNewswire)
Oct-26-25 06:16AM	Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum (Insider Monkey)
Oct-17-25 06:00AM	I-Mab morphs into hub-and-spoke biotech; Astellas passes on Taysha gene therapy (BioPharma Dive) -7.09%
03:14AM	Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Oct-16-25 04:01PM	Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome (GlobeNewswire)
Oct-09-25 08:00AM	Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting (GlobeNewswire)
Oct-03-25 04:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.14%
Oct-02-25 08:00AM	Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome (GlobeNewswire) +53.46%
Sep-05-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-25 11:56PM	Piper Sandler Maintains a Buy on Taysha Gene Therapies (TSHA), Sets a PT of $9 (Insider Monkey)
Aug-13-25 03:07AM	Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... (GuruFocus.com)
Aug-12-25 03:00PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +5.43%
08:01AM	Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:27AM	Earnings To Watch: Taysha Gene Therapies Inc (TSHA) Reports Q2 2025 Result (GuruFocus.com)
Aug-07-25 05:15PM	Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-05-25 04:05PM	Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 (GlobeNewswire)
Aug-04-25 10:01AM	Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) (Insider Monkey)
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know (Zacks)
Aug-01-25 05:06PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
06:47AM	BofA Securities Affirms 'Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects (Insider Monkey)
Jul-22-25 06:54AM	Leigh Syndrome Market Research Report 2025-2035 \| Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics (GlobeNewswire)
Jul-16-25 12:00PM	Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jul-03-25 01:05PM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:08AM	Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Jun-24-25 03:51PM	Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT (Insider Monkey)
Jun-18-25 09:16AM	Craig-Hallum bullish on Neurogene, initiates with a Buy (TipRanks)
Jun-06-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-25 05:17PM	Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program (GlobeNewswire)
May-29-25 12:12AM	Taysha Gene Therapies, Inc. (TSHA)'s TSHA-102 Shows Promising Results in Rett Syndrome Patients Aged 6+ (Insider Monkey) +12.70%
May-28-25 10:40PM	Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -6.33%
04:02PM	Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:01PM	Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102 (GlobeNewswire)
May-16-25 03:19AM	Q1 2025 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents) +5.47%
03:09AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Call Highlights: Promising Clinical Progress ... (GuruFocus.com)
May-15-25 09:10AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.02%
08:00AM	Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-25 09:40AM	Taysha Gene Therapies Inc (TSHA) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.53%
04:05PM	Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15 (GlobeNewswire)
May-06-25 05:55PM	Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -18.70% -5.00%
10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
May-02-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Apr-21-25 10:00AM	Pz-Cel Has Massive Potential For RDEB Patients (Seeking Alpha) +16.94%
Apr-15-25 04:04PM	Taysha Gene Therapies: Sell Rating On Uncertain Pipeline Prospects And Limited Opportunity (Seeking Alpha) -7.09%
Apr-04-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -8.99%
Mar-19-25 04:31PM	Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? (InsiderMonkey) +5.17% -7.10%
Mar-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 01:04AM	Q4 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-25 09:15AM	Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-25 10:57AM	Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-19-25 08:00AM	Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 (GlobeNewswire)
Feb-07-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.42%
Jan-03-25 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-06-24 08:00AM	Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-24 12:51PM	Q3 2024 Taysha Gene Therapies Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ... (GuruFocus.com)
Nov-13-24 05:15PM	Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -7.53%
04:01PM	Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nagendran Sukumar	President and Head of R&D	Jul 10 '26	Sale	6.24	200,000	1,248,000	936,410	Jul 10 06:54 PM
Nagendran Sukumar	Officer	Jul 10 '26	Proposed Sale	6.49	200,000	1,298,000		Jul 10 04:21 PM
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Option Exercise	1.71	19,021	32,526	1,336,410	Apr 13 04:33 PM
Nagendran Sukumar	President and Head of R&D	Apr 10 '26	Sale	4.46	200,000	892,000	1,136,410	Apr 13 04:33 PM
Nagendran Sukumar	Officer	Apr 10 '26	Proposed Sale	4.63	200,000	926,000		Apr 10 04:11 PM
Rumana Haque-Ahmed	Officer	Feb 27 '26	Proposed Sale	4.57	2,405	10,991		Feb 27 04:07 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	4.52	1,655	7,481	1,442,131	Feb 06 04:30 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Feb 04 '26	Proposed Sale	4.72	901	4,253		Feb 04 06:44 PM
Fred Porter	Affiliate-Chief of Staff &	Feb 04 '26	Proposed Sale	4.72	889	4,196		Feb 04 06:42 PM
Sean McAuliffe	Affiliate - Chief Business Off	Feb 04 '26	Proposed Sale	4.72	914	4,314		Feb 04 06:41 PM
Rumana Haque-Ahmed	Officer	Feb 04 '26	Proposed Sale	4.72	697	3,290		Feb 04 06:39 PM
Kamran Alam	Officer	Feb 04 '26	Proposed Sale	4.72	1,655	7,812		Feb 04 06:38 PM
Nagendran Sukumar	President and Head of R&D	Jan 23 '26	Sale	4.75	89,132	423,377	1,344,307	Jan 27 04:05 PM
Nagendran Sukumar	President and Head of R&D	Jan 26 '26	Sale	4.61	26,918	124,092	1,317,389	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 23 '26	Sale	4.75	136,789	649,748	2,949,569	Jan 27 04:05 PM
Nolan Sean P.	Chief Executive Officer	Jan 26 '26	Sale	4.61	41,312	190,448	2,908,257	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 23 '26	Sale	4.75	78,968	375,098	1,467,635	Jan 27 04:05 PM
Alam Kamran	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	4.61	23,849	109,944	1,443,786	Jan 27 04:05 PM
Sean P. Nolan	Officer	Jan 23 '26	Proposed Sale	5.09	168,078	855,517		Jan 23 08:07 PM
Sukumar Nagendran	Officer	Jan 23 '26	Proposed Sale	5.09	113,824	579,364		Jan 23 08:05 PM
Rumana Haque-Ahmed	Officer	Jan 23 '26	Proposed Sale	5.09	30,052	152,965		Jan 23 08:04 PM
Fred Porter	Affiliate-Chief of Staff &	Jan 23 '26	Proposed Sale	5.09	54,916	279,522		Jan 23 08:02 PM
Emily McGinnis	Affiliate-Chief Pat. Adv. &	Jan 23 '26	Proposed Sale	5.09	32,077	163,272		Jan 23 08:01 PM
Sean McAuliffe	Affiliate - Chief Business Off	Jan 23 '26	Proposed Sale	5.09	46,064	234,466		Jan 23 07:59 PM
Kamran Alam	Officer	Jan 23 '26	Proposed Sale	5.09	100,846	513,306		Jan 23 07:58 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Option Exercise	1.15	200,000	229,440	1,206,439	Jan 14 04:45 PM
Nagendran Sukumar	President and Head of R&D	Jan 12 '26	Sale	4.71	200,000	942,000	1,006,439	Jan 14 04:45 PM
Nagendran Sukumar	Officer	Jan 12 '26	Proposed Sale	4.98	200,000	996,000		Jan 12 04:19 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Option Exercise	1.71	260,047	444,680	1,266,486	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Option Exercise	1.07	110,125	117,363	1,116,564	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Dec 01 '25	Sale	4.51	260,047	1,172,812	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	President and Head of R&D	Nov 28 '25	Sale	4.75	110,125	523,094	1,006,439	Dec 01 08:58 PM
Nagendran Sukumar	Officer	Nov 28 '25	Proposed Sale	4.86	370,172	1,799,036		Nov 28 01:07 PM

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

CEO & ChairmanMr. Sean P. Nolan

PresidentDr. Sukumar Nagendran M.D.

M.B.A.Mr. Kamran Alam CPA

Director of Corporate Communications & Investor RelationsHayleigh Collins

Chief Legal Officer & Corporate SecretaryMr. Michael B. Johannesen

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Taysha Gene Therapies Inc

Upgrade your Finviz experience